SS
CTMX icon

Steve Schonfeld’s CytomX Therapeutics CTMX Stock Holding History

Steve Schonfeld’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-67,732
Closed -$318K – 2679
2026
Q1 		$318K Buy
+67,732
New +$344K ﹤0.01% 1555
2025
Q2 		– Sell
-589,332
Closed -$375K – 2121
2025
Q1 		$375K Sell
589,332
-791,468
-57% -$614K ﹤0.01% 1705
2024
Q4 		$1.42M Buy
1,380,800
+169,000
+14% +$182K 0.01% 978
2024
Q3 		$1.43M Sell
1,211,800
-163,490
-12% -$208K 0.01% 1032
2024
Q2 		$1.68M Buy
1,375,290
+100,783
+8% +$201K 0.01% 982
2024
Q1 		$2.78M Buy
+1,274,507
New +$2.35M 0.02% 874
2022
Q1 		– Sell
-19,800
Closed -$85K – 2646
2021
Q4 		$85K Buy
+19,800
New +$116K ﹤0.01% 1905

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Steve Schonfeld's CTMX Position: Q2 2026 in Review

Steve Schonfeld sold out of CytomX Therapeutics (CTMX) in Q2 2026, closing a stake of 67,732 shares — an estimated $318K sold.

Steve Schonfeld first reported a position in CTMX in Q4 2021 and held it in 7 quarters. The position peaked at $2.78M in Q1 2024. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Steve Schonfeld reported no remaining CytomX Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Steve Schonfeld sold 67,732 CytomX Therapeutics shares in Q2 2026, an estimated $318K.
  • Steve Schonfeld first reported a position in CytomX Therapeutics in Q4 2021 and held it in 7 quarters.
  • Steve Schonfeld's CytomX Therapeutics position peaked at $2.78M in Q1 2024.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.